Attached files
| file | filename |
|---|---|
| EX-10.13 - EX-10.13 - Frequency Therapeutics, Inc. | freq-ex1013_758.htm |
| 10-K - 10-K - Frequency Therapeutics, Inc. | freq-10k_20191231.htm |
| EX-32.2 - EX-32.2 - Frequency Therapeutics, Inc. | freq-ex322_6.htm |
| EX-32.1 - EX-32.1 - Frequency Therapeutics, Inc. | freq-ex321_7.htm |
| EX-31.2 - EX-31.2 - Frequency Therapeutics, Inc. | freq-ex312_8.htm |
| EX-31.1 - EX-31.1 - Frequency Therapeutics, Inc. | freq-ex311_9.htm |
| EX-21.1 - EX-21.1 - Frequency Therapeutics, Inc. | freq-ex211_757.htm |
| EX-10.5.1 - EX-10.5.1 - Frequency Therapeutics, Inc. | exhibit10_51.htm |
| EX-4.3 - EX-4.3 - Frequency Therapeutics, Inc. | freq-ex43_875.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement (No. 333-234128) on Form S-8 of Frequency Therapeutics, Inc. of our report dated March 26, 2020, relating to the consolidated financial statements of Frequency Therapeutics, Inc. and subsidiaries appearing in this Annual Report on Form 10-K of Frequency Therapeutics, Inc. for the year ended December 31, 2019.
/s/ RSM US LLP
Boston, Massachusetts
March 26, 2020